Patents Assigned to NovaRx
  • Genetically modified cells expressing a TGF beta inhibitor, the cells being lung cancer cells
    Patent number: 7740837
    Abstract: The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGF? inhibitor effective to reduce expression of TGF?, where the genetically modified cells are non-small cell lung cancer (NSCLC) cells or small cell lung cancer (SCLC) cells, and related methods.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: June 22, 2010
    Assignee: Novarx
    Inventor: Habib Fakhrai
  • Genetically modified cells expressing a TGF? inhibitor, the cells being lung cancer cells
    Patent number: 7101543
    Abstract: The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGF? inhibitor effective to reduce expression of TGF?, where the genetically modified cells are non-small cell lung cancer (NSCLC) cells or small cell lung cancer (SCLC) cells, and related methods.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: September 5, 2006
    Assignee: NovaRx
    Inventor: Habib Fakhrai